Viridian Therapeutics Inc

VRDN

Add to Watchlist

16.820USD

-0.610-3.50%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Viridian Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

38 / 382

Overall Ranking

139 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Viridian Therapeutics Inc Highlights

StrengthsRisks

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22463.38% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 70.85M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 70.85M.

Fairly Valued

The company’s latest PE is -4.21, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 116.15M shares, increasing 5.38% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 68.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.30.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

32.933

Target Price

+88.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Viridian Therapeutics Inc is 6.25, ranking 264 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 141.00K, representing a year-over-year increase of 95.83%, while its net profit experienced a year-over-year increase of 20.70%.

Score

Industry at a Glance

Previous score

6.25

Change

0



Financials

7.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.77

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.79

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Viridian Therapeutics Inc is 5.95, ranking 337 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.21, which is -48.58% below the recent high of -2.16 and -120.80% above the recent low of -9.29.

Score

Industry at a Glance

Previous score

5.95

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Viridian Therapeutics Inc is 8.53, ranking 106 out of 382 in the Biotechnology & Medical Research industry. The average price target is 40.50, with a high of 50.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

8.59

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Viridian Therapeutics Inc is 7.52, ranking 58 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 20.15 and the support level at 13.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.96

Change

-1.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Viridian Therapeutics Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 112.73%, representing a quarter-over-quarter increase of 8.27%. The largest institutional shareholder is PRFDX, holding a total of 3.36M shares, representing 3.04% of shares outstanding, with 53.38% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

12.41M

+13.89%

BlackRock Institutional Trust Company, N.A.

5.55M

+17.49%

Deep Track Capital LP

2.52M

-53.07%

Bellevue Asset Management AG

4.36M

+155506.10%

Fairmount Funds Management LLC

3.91M

--

VR Adviser, LLC

3.88M

--

State Street Investment Management (US)

3.47M

+35.72%

T. Rowe Price Associates, Inc.

Star Investors

3.36M

+43.17%

Perceptive Advisors LLC

3.04M

+108.06%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Viridian Therapeutics Inc is 6.52, ranking 23 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Viridian Therapeutics Inc

VRDN

7.32 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment